Why the "SAFE Drugs Act" Isn't Safe for Patients | Essential: The Pharmacy Compounding Podcast

In this episode, Andrew Kantor is joined by federal lobbyist David Pore and PCCA's Amy Shank to examine the proposed SAFE Act and its potential impact on compounding pharmacies. The discussion explores concerns that the bill could restrict patient access to compounded medications during drug shortages, impose new limitations on 503A pharmacies, and disproportionately affect legitimate compounders while failing to address bad actors. The episode also unpacks the legislation's connection to GLP-1 demand, adverse event reporting, and the bipartisan politics surrounding the bill, while encouraging listeners to stay engaged in APC's advocacy efforts.